Search Results

You are looking at 1 - 10 of 14 items for :

  • "Retinopathy" x
  • Refine by Access: All x
Clear All
Full access

Irene Dy, Rangaswamy Chintapatla, Isabel Preeshagul, and Daniel Becker

-related autoimmune retinopathy and was referred to an oncologist for further evaluation. She had no detectable antiretinal antibodies. She was a nonsmoker with no significant past medical history. She denied weight loss, fever, abdominal pain, dysuria, vaginal

Full access

Rohan Maniar, Stephanie M. Gallitano, Sameera Husain, Golnaz Moazami, Michael J. Weiss, and Catherine A. Shu

and 20/150 in the left eye. BRAF/MEK inhibition was discontinued immediately given concern for serous retinopathy/uveitis, and the patient was started on topical corticosteroid drops with no improvement and even progression of symptoms. On repeat

Full access

Leena Gandhi and Bruce E. Johnson

cerebellar degeneration . Nat Med 1998 ; 4 : 1321 – 1324 . 40. Polans AS Witkowska D Haley TL . Recoverin, a photoreceptor-specific calcium-binding protein, is expressed by the tumor of a patient with cancer-associated retinopathy . Proc Natl

Full access

Presenter: Arlene O. Siefker-Radtke

retinopathy were frequently reported in this population. Clinicians should be informed about how to prevent and treat these conditions, which may include dose modifications, over-the-counter and prescription medications, lifestyle adjustments, and, when

Full access

Kevin O’Brien, Rahul Dave, Skand Shekhar, Fady Hannah-Shmouni, Leora E. Comis, Beth I. Solomon, Marcus Chen, William A. Gahl, Edmond FitzGibbon, Bernadette R. Gochuico, and Juvianee I. Estrada-Veras

. Additionally, some medications are associated with rare but serious ocular complications, such as retinal vein occlusion 56 and retinopathy, whereas radiation treatment for proptosis may result in cataracts and retinopathy. 57 The National Registry of Drug

Full access

Jorge Cortes and Francis Giles

. The kinase inhibitor PKC412 suppresses epiretinal membrane formation and retinal detachment in mice with proliferative retinopathies . Invest Ophthalmol Vis Sci 2003 ; 44 : 3656 – 3662 . 92 Sotlar K Marafioti T Griesser H . Detection of

Full access

NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019

Featured Updates to the NCCN Guidelines

P. Kumar Rao, Christopher Barker, Daniel G. Coit, Richard W. Joseph, Miguel Materin, Ramesh Rengan, Jeffrey Sosman, John A. Thompson, Mark R. Albertini, Genevieve Boland, William E. Carson III, Carlo Contreras, Gregory A. Daniels, Dominick DiMaio, Alison Durham, Ryan C. Fields, Martin D. Fleming, Anjela Galan, Brian Gastman, Kenneth Grossman, Valerie Guild, Douglas Johnson, Giorgos Karakousis, Julie R. Lange, ScM, Kim Margolin, Sameer Nath, Anthony J. Olszanski, Patrick A. Ott, Merrick I. Ross, April K. Salama, Joseph Skitzki, Susan M. Swetter, Evan Wuthrick, Nicole R. McMillian, and Anita Engh

, and secondary enucleation were similar across treatments. 86 Risk of cataract appeared similar across treatments, but SRS appeared to be associated with higher rates of certain complications, including neovascular glaucoma, radiation retinopathy, and

Full access

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Ignacio Garrido-Laguna, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory, and Deborah A. Freedman-Cass

tolerated in 30 patients, with dose-limiting toxicities in 5 patients (cetuximab infusion reaction, n=2; grade 2 retinopathy, n=2; grade 2 decreased ejection fraction, n=1). Of the 30 patients, 19 (63%) experienced a grade 3 or 4 AE, including fatigue (grade

Full access

Ronald S. Go, Eric Jacobsen, Robert Baiocchi, Ilia Buhtoiarov, Erin B. Butler, Patrick K. Campbell, Don W. Coulter, Eli Diamond, Aron Flagg, Aaron M. Goodman, Gaurav Goyal, Dita Gratzinger, Paul C. Hendrie, Meghan Higman, Michael D. Hogarty, Filip Janku, Reem Karmali, David Morgan, Anne C. Raldow, Alexandra Stefanovic, Srinivas K. Tantravahi, Kelly Walkovich, Ling Zhang, Mary Anne Bergman, and Susan D. Darlow

due to the high incidence of serous retinopathy with MEK inhibitors. 31 , 32 Histopathologic Characterization of LCH LCH tumors often demonstrate neoplastic histiocytes admixed with marked inflammatory cell infiltration. On hematoxylin and eosin

Full access

Daniel G. Coit, John A. Thompson, Mark R. Albertini, Christopher Barker, William E. Carson III, Carlo Contreras, Gregory A. Daniels, Dominick DiMaio, Ryan C. Fields, Martin D. Fleming, Morganna Freeman, Anjela Galan, Brian Gastman, Valerie Guild, Douglas Johnson, Richard W. Joseph, Julie R. Lange, Sameer Nath, Anthony J. Olszanski, Patrick Ott, Aparna Priyanath Gupta, Merrick I. Ross, April K. Salama, Joseph Skitzki, Jeffrey Sosman, Susan M. Swetter, Kenneth K. Tanabe, Evan Wuthrick, Nicole R. McMillian, and Anita M. Engh

Table 10 , reports from multiple clinical trials have highlighted a few other rare high-grade AEs of special interest, including an assortment of ocular AEs (eg, retinopathies, blurred vision, retinal detachment, uveitis), QT prolongation, decreased